|
ANUBL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
3.32867067243114E-12 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
9.997000E-01 |
| Stage1-vs-Stage3 |
6.075400E-03 |
| Stage1-vs-Stage4 |
1.74810000030945E-07 |
| Stage2-vs-Stage3 |
6.721500E-02 |
| Stage2-vs-Stage4 |
1.437640E-04 |
| Stage3-vs-Stage4 |
2.096000E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
5.2154000007576E-09 |
| Normal-vs-Asian |
1.62891922173003E-12 |
| Caucasian-vs-AfricanAmerican |
5.427400E-01 |
| Caucasian-vs-Asian |
9.727400E-01 |
| AfricanAmerican-vs-Asian |
5.624200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
6.283500E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
1.62010000004376E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.652300E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.638000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.097200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.918200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.180600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.569400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.22970000000245E-05 |
| Classical-VS-Follicular |
1.655230E-01 |
| Classical-VS-Other |
4.236400E-01 |
| Classical-VS-Normal |
1.63158375698913E-12 |
| Tall-VS-Follicular |
1.92375999999994E-05 |
| Tall-VS-Other |
2.682000E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
2.760800E-01 |
| Follicular-VS-Normal |
3.06554781559498E-12 |
| Other-VS-Normal |
3.55990000000528E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.44249065417534E-15 |
| N0-vs-N1 |
8.672200E-02 |
|
|
